Skip to ContentSkip to Navigation
University of Groningenfounded in 1614  -  top 100 university
About us Practical matters How to find us V.D. de Jager

Publications

Corrigendum to "Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands" [Eur J Cancer 205 (2024)114125]

Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients

Fostering the implementation of liquid biopsy in clinical practice: meeting report 2024 of the European Liquid Biopsy Society (ELBS)

Large language model-based approach for low-cost, rapid and accurate automated extraction of predictive biomarker testing results from Dutch pathology reports

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop

112P Reporting of molecular test results from cell-free DNA analyses: Expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA workshop

Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Press/media

European Liquid Biopsy Society geeft advies over de rapportage van ctDNA-testuitslagen